tirzepatide pediatrics Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Zepbound Now Available Through LillyDirect:

The starting dose is 1.5 mg daily, escalating through 3 mg, 7 mg, and 14 mg before reaching the target dose of 25 mg

Semaglutide is a GLP-1 receptor agonist that increases insulin release, slows stomach emptying, and signals fullness to the brain

That is the honest read of the 2025 tirzepatide vs semaglutide evidence, and it is why EASO 2025 guidelines treat both drugs as first-line with tirzepatide favored for obesity without CV disease

Thats actually down from 16 states recently several states have recently eliminated obesity drug coverage due to budget pressures, including California, New Hampshire, Pennsylvania, and South Carolina

For instance, research has shown that semaglutide can reduce inflammation, which is a significant factor in many chronic pain conditions